|
Report Date : |
03.09.2012 |
IDENTIFICATION DETAILS
|
Name : |
TEVA CZECH INDUSTRIES S.R.O. |
|
|
|
|
Formerly Known As : |
IVAX Pharmaceuticals s.r.o. |
|
|
|
|
Registered Office : |
Ostravská 29/305, 747 70 Opava,
Komárov |
|
|
|
|
Country : |
Czech Republic |
|
|
|
|
Financials (as on) : |
31.12.2011 |
|
|
|
|
Date of Incorporation : |
31.12.2002 |
|
|
|
|
Com. Reg. No.: |
C/27159 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture of basic pharmaceutical products |
|
|
|
|
No. of Employees : |
1450 employees |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2012
|
Country Name |
Previous Rating (31.12.2011) |
Current Rating (31.03.2012) |
|
Czech republic |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Czech Republic - ECONOMIC OVERVIEW
The Czech Republic is a stable and prosperous market economy, which harmonized its laws and regulations with those of the EU prior to its EU accession in 2004. While the conservative, inward-looking Czech financial system has remained relatively healthy, the small, open, export-driven Czech economy remains sensitive to changes in the economic performance of its main export markets, especially Germany. When Western Europe and Germany fell into recession in late 2008, demand for Czech goods plunged, leading to double digit drops in industrial production and exports. As a result, real GDP fell 4.7% in 2009, with most of the decline occurring during the first quarter. Real GDP, however, has slowly recovered with positive quarter-on-quarter growth starting in the second half of 2009 and continuing throughout 2011. The auto industry remains the largest single industry, and, together with its upstream suppliers, accounts for nearly 24% of Czech manufacturing. The Czech Republic produced more than a million cars for the first time in 2010, over 80% of which were exported. Foreign and domestic businesses alike voice concerns about corruption especially in public procurement. Other long term challenges include dealing with a rapidly aging population, funding an unsustainable pension and health care system, and diversifying away from manufacturing and toward a more high-tech, services-based, knowledge economy.
|
Source : CIA |
Teva Czech Industries s.r.o.
Ostravská 29/305
747 70 Opava, Komárov
telephone: 00420/ 553 641 111
telefax: 00420/ 553 642 150
e-mail: public-relations@ivax-cz.com
Web: www.ivax-cz.com
|
Company development |
Positive company
development |
|
|
Order situation |
Good order
situation |
|
|
Terms of payment |
mostly within
agreed terms, but partly also delayed |
|
|
Business
connection |
Business
connections appear permissible |
|
|
|
||
|
Legal form |
Private limited company |
|
|
Foundation |
31/12/2002 - Private limited company |
|
Comp. Register |
31/12/2002, Krajský soud v
Ostravě, RegNr.: C/27159 |
|
Share Capital |
31/12/2002 |
CZK |
2 500 000 000,- |
|
|
Shareholders |
Ivax
International B.V. |
CZK |
2 500 000 000,- |
|
|
Management |
Jiří
Urbanec, MBA (06.03.1959) |
|
|
JUDr. Hana
Lasáková, MBA (15.11.1960) |
|
|
Ing. Lubomír
Roder (18.07.1953) |
|
General Data |
Manufacture,
packing and sale of generic treatment preparations, |
|
|
Main activity: |
|
|
|
|
Former name(s) |
||
|
|
Trade name(s) |
||
|
|
Export: |
85% |
|
|
|
Import: |
|
|
|
|
|
||
|
|
Address: |
||
|
Staff |
2008 |
999 employees |
|
|
|
2009 |
1016 employees |
|
|
2010 |
1280 employees |
|
|
2011 |
1460 employees |
|
|
2012 |
1450 employees |
|
|
Due to increase volume of orders for the
USA, the company has extended volume of production. In connection with this,
there was also increase to number of employees. |
|||||
|
Annual Sales |
2005 |
actual sales |
CZK |
4 460 879 000,- |
|
|
|
|
2006 |
actual sales |
CZK |
5 078 059 000,- |
|
|
|
2007 |
actual sales |
CZK |
6 091 103 000,- |
|
|
|
2008 |
actual sales |
CZK |
4 814 049 000,- |
|
|
|
2009 |
actual sales |
CZK |
5 412 044 000,- |
|
|
|
2010 |
actual sales |
CZK |
6 750 870 000,- |
|
|
|
2011 |
actual sales |
CZK |
8 673 486 000,- |
|
|
Property |
Property of the company: property |
|
Balance sheets |
The enclosed balance of 2011 from business
register, it is authenticated by the auditor. (31.12.2011 - 1 CZK) |
|
|
The enclosed profit/loss account of 2011
from business register, it is authenticated by the auditor. (31.12.2011 - 1
CZK) |
|
Remarks |
All the sources
of negative data accessible to public (insolvency registers, databases of
debtors of health insurance institutions, commercial bulletin, collection
database) are currently monitored. |
|
|
Business management: |
|
|
Bankers |
Citibank Europe plc, organizační
složka |
|
|
Copyright:
s.r.o. Praha |
This information is addressed exclusively
to the addressee. Contractor obligates to provide updated information.
Although it is always put maximum effort to collect actual and exact
information, it is not confirmed as delinquency if there are particular
inaccurateness contained within the information, which are not considered as
essential in terms of the objective for which the information is provided to
the addressee. Contractor and recipient conform to the rules of the Name and
Description Security Act, Nub.101/2000. According to the Name and Description
Security Act, recipient has the right to process or to use forwarding data
only for the purpose for which information has been sent to the recipient.
Usage for other purpose is acceptable only in case referring to valid
regulations of the above mentioned act. |
|
|
balance |
31.12.2008 (CZK) |
31.12.2009 (CZK) |
31.12.2010 (CZK) |
31.12.2011 (CZK) |
|
r1 |
TOTAL ASSETS |
8 596 968 000 |
9 376 465 000 |
11 286 847 000 |
13 610 151 000 |
|
r2 |
Receivables for subscriptions |
|
0 |
0 |
0 |
|
r3 |
Fixed assets |
1 894 917 000 |
3 020 710 000 |
3 562 443 000 |
4 174 006 000 |
|
r4 |
Intangible fixed
assets |
198 663 000 |
236 104 000 |
251 542 000 |
270 793 000 |
|
r5 |
Incorporation expenses |
|
0 |
0 |
0 |
|
r6 |
Research and development |
|
0 |
0 |
0 |
|
r7 |
Software |
10 826 000 |
10 031 000 |
31 257 000 |
88 720 000 |
|
r8 |
Valuable rights |
62 303 000 |
50 977 000 |
63 535 000 |
52 011 000 |
|
r9 |
Goodwill |
|
0 |
0 |
0 |
|
r10 |
Other intangible fixed assets |
521 000 |
691 000 |
1 442 000 |
1 114 000 |
|
r11 |
Intangible fixed assets under construction |
125 013 000 |
174 405 000 |
146 875 000 |
128 948 000 |
|
r12 |
Advance payments for intangible fixed
assets |
|
0 |
8 433 000 |
0 |
|
r13 |
Tangible fixed
assets |
1 695 932 000 |
2 784 284 000 |
3 310 901 000 |
3 903 213 000 |
|
r14 |
Lands |
86 508 000 |
87 460 000 |
87 460 000 |
101 592 000 |
|
r15 |
Constructions |
651 652 000 |
649 992 000 |
1 105 620 000 |
1 116 739 000 |
|
r16 |
Equipment |
790 797 000 |
936 818 000 |
1 679 179 000 |
1 936 029 000 |
|
r17 |
Perennial corps |
|
0 |
0 |
0 |
|
r18 |
Breeding and draught animals |
|
0 |
0 |
0 |
|
r19 |
Other tangible fixed assets |
209 000 |
210 000 |
209 000 |
209 000 |
|
r20 |
Tangible fixed assets under construction |
164 822 000 |
1 091 755 000 |
211 686 000 |
682 449 000 |
|
r21 |
Advance payments for tangible fixed assets |
1 944 000 |
18 049 000 |
226 747 000 |
66 195 000 |
|
r22 |
Adjustment to acquired assets |
|
0 |
0 |
0 |
|
r23 |
Long-term
financial assets |
322 000 |
322 000 |
0 |
0 |
|
r24 |
Shares in controlled and managed
organizations |
322 000 |
322 000 |
0 |
0 |
|
r25 |
Shares in accounting units with
substantial influence |
|
0 |
0 |
0 |
|
r26 |
Other securities and shares |
0 |
0 |
0 |
0 |
|
r27 |
Loans to controlled and managed
organizations and to accounting unit with substantial influence |
|
0 |
0 |
0 |
|
r28 |
Other financial investments |
|
0 |
0 |
0 |
|
r29 |
Financial investments acquired |
|
0 |
0 |
0 |
|
r30 |
Advance payments for long-term financial
assets |
|
0 |
0 |
0 |
|
r31 |
Current assets |
6 598 249 000 |
6 259 724 000 |
7 552 868 000 |
9 268 248 000 |
|
r32 |
Inventory |
1 915 578 000 |
2 124 900 000 |
2 474 036 000 |
2 597 575 000 |
|
r33 |
Materials |
609 191 000 |
573 704 000 |
790 749 000 |
928 799 000 |
|
r34 |
Work in progress and semi-products |
364 085 000 |
564 517 000 |
703 842 000 |
666 864 000 |
|
r35 |
Finished products |
766 682 000 |
628 933 000 |
711 670 000 |
828 014 000 |
|
r36 |
Animals |
|
0 |
0 |
0 |
|
r37 |
Merchandise |
170 963 000 |
335 213 000 |
266 031 000 |
151 552 000 |
|
r38 |
Advance payments for inventory |
4 657 000 |
22 533 000 |
1 744 000 |
22 346 000 |
|
r39 |
Long-term
receivables |
527 999 000 |
1 236 580 000 |
2 213 808 000 |
1 627 574 000 |
|
r40 |
Trade receivables |
|
1 223 051 000 |
2 213 738 000 |
1 556 400 000 |
|
r41 |
Receivables from controlled and managed organizations |
518 280 000 |
0 |
0 |
75 000 |
|
r42 |
Receivables from accounting units with
substantial influence |
|
0 |
0 |
71 099 000 |
|
r43 |
Receivables from partners, cooperative
members and association members |
|
0 |
0 |
0 |
|
r44 |
Long-term deposits given |
163 000 |
66 000 |
70 000 |
0 |
|
r45 |
Estimated receivable |
|
0 |
0 |
0 |
|
r46 |
Other receivables |
|
0 |
0 |
0 |
|
r47 |
Deferred tax receivable |
9 556 000 |
13 463 000 |
0 |
0 |
|
r48 |
Short-term
receivables |
2 654 180 000 |
2 606 843 000 |
2 855 520 000 |
4 928 943 000 |
|
r49 |
Trade receivables |
1 978 549 000 |
1 999 764 000 |
2 617 551 000 |
3 024 494 000 |
|
r50 |
Receivables from controlled and managed
organizations |
525 140 000 |
395 160 000 |
0 |
0 |
|
r51 |
Receivables from accounting units with
substantial influence |
|
0 |
113 317 000 |
0 |
|
r52 |
Receivables from partners, cooperative
members and association members |
|
0 |
0 |
1 618 215 000 |
|
r53 |
Receivables from social security and health
insurance |
|
0 |
0 |
0 |
|
r54 |
Due from state - tax receivable |
135 257 000 |
133 742 000 |
65 683 000 |
58 895 000 |
|
r55 |
Short-term deposits given |
14 634 000 |
17 385 000 |
8 807 000 |
32 173 000 |
|
r56 |
Estimated receivable |
|
0 |
49 636 000 |
194 735 000 |
|
r57 |
Other receivables |
600 000 |
60 792 000 |
526 000 |
431 000 |
|
r58 |
Short-term
financial assets |
1 500 492 000 |
291 401 000 |
9 504 000 |
114 156 000 |
|
r59 |
Cash |
668 000 |
663 000 |
910 000 |
538 000 |
|
r60 |
Bank accounts |
1 499 824 000 |
290 738 000 |
8 594 000 |
113 618 000 |
|
r61 |
Short-term securities and ownership
interests |
|
0 |
0 |
0 |
|
r62 |
Short-term financial assets acquired |
|
0 |
0 |
0 |
|
r63 |
Accruals |
103 802 000 |
96 031 000 |
171 536 000 |
167 897 000 |
|
r64 |
Deferred expenses |
19 094 000 |
22 026 000 |
27 527 000 |
28 261 000 |
|
r65 |
Complex deferred costs |
1 383 000 |
51 261 000 |
130 437 000 |
107 107 000 |
|
r66 |
Deferred income |
83 325 000 |
22 744 000 |
13 572 000 |
32 529 000 |
|
r67 |
TOTAL
LIABILITIES |
8 596 968 000 |
9 376 465 000 |
11 286 847 000 |
13 610 151 000 |
|
r68 |
Equity |
7 283 959 000 |
8 132 114 000 |
9 415 401 000 |
11 958 027 000 |
|
r69 |
Registered
capital |
2 500 000 000 |
2 500 000 000 |
2 500 000 000 |
2 500 000 000 |
|
r70 |
Registered capital |
2 500 000 000 |
2 500 000 000 |
2 500 000 000 |
2 500 000 000 |
|
r71 |
Company’s own shares and ownership
interests (-) |
|
0 |
0 |
0 |
|
r72 |
Changes of registered capital ( +/- ) |
|
0 |
0 |
0 |
|
r73 |
Capital funds |
|
0 |
0 |
0 |
|
r74 |
Share premium |
|
0 |
0 |
0 |
|
r75 |
Other capital funds |
|
0 |
0 |
0 |
|
r76 |
Differences from revaluation of assets and
liabilities ( +/- ) |
|
0 |
0 |
0 |
|
r77 |
Differences from revaluation in transformation
( +/- ) |
|
0 |
0 |
0 |
|
r78 |
Reserve funds,
statutory reserve account for cooperatives, and other retained earnings |
250 000 000 |
250 000 000 |
250 000 000 |
250 000 000 |
|
r79 |
Legal reserve fund / indivisible fund |
250 000 000 |
250 000 000 |
250 000 000 |
250 000 000 |
|
r80 |
Statutory and other funds |
|
0 |
0 |
0 |
|
r81 |
Profit / loss -
previous years |
3 480 572 000 |
4 533 959 000 |
5 382 114 000 |
6 665 401 000 |
|
r82 |
Retained earnings from previous years |
3 480 572 000 |
4 533 959 000 |
5 382 114 000 |
6 665 401 000 |
|
r83 |
Accumulated losses from previous years |
|
0 |
0 |
0 |
|
r84 |
Profit / loss -
current year (+/-) |
1 053 387 000 |
848 155 000 |
1 283 287 000 |
2 542 626 000 |
|
r85 |
Other sources |
1 292 674 000 |
1 216 942 000 |
1 847 894 000 |
1 608 357 000 |
|
r86 |
Reserves |
298 764 000 |
295 493 000 |
266 345 000 |
342 616 000 |
|
r87 |
Reserves under special statutory
regulations |
|
0 |
0 |
0 |
|
r88 |
Reserves for pension and similar payables |
|
0 |
0 |
0 |
|
r89 |
Income tax reserves |
|
0 |
0 |
0 |
|
r90 |
Other reserves |
298 764 000 |
295 493 000 |
266 345 000 |
342 616 000 |
|
r91 |
Long-term
payables |
0 |
0 |
33 655 000 |
0 |
|
r92 |
Trade payables |
|
0 |
0 |
0 |
|
r93 |
Payables to controlled and managed
organizations |
|
0 |
0 |
0 |
|
r94 |
Payables to accounting units with
substantial influence |
|
0 |
0 |
0 |
|
r95 |
Payables from partners, cooperative
members and association members |
|
0 |
0 |
0 |
|
r96 |
Long-term advances received |
|
0 |
0 |
0 |
|
r97 |
Issues bonds |
|
0 |
0 |
0 |
|
r98 |
Long-term notes payables |
|
0 |
0 |
0 |
|
r99 |
Estimated payables |
|
0 |
0 |
0 |
|
r100 |
Other payables |
|
0 |
0 |
0 |
|
r101 |
Deferred tax liability |
0 |
0 |
33 655 000 |
0 |
|
r102 |
Short-term
payables |
993 910 000 |
921 449 000 |
1 547 894 000 |
1 265 741 000 |
|
r103 |
Trade payables |
814 102 000 |
766 316 000 |
1 409 532 000 |
985 002 000 |
|
r104 |
Payables to controlled and managed
organizations |
|
57 579 000 |
0 |
0 |
|
r105 |
Payables to accounting units with
substantial influence |
|
0 |
12 128 000 |
0 |
|
r106 |
Payables from partners, cooperative
members and association members |
40 305 000 |
0 |
0 |
0 |
|
r107 |
Payroll |
20 393 000 |
27 337 000 |
29 713 000 |
31 983 000 |
|
r108 |
Payables to social securities and health
insurance |
9 847 000 |
12 454 000 |
16 357 000 |
17 120 000 |
|
r109 |
Due from state - tax liabilities and
subsidies |
3 734 000 |
5 042 000 |
6 011 000 |
6 209 000 |
|
r110 |
Short-term deposits received |
4 366 000 |
1 138 000 |
1 290 000 |
273 000 |
|
r111 |
Issues bonds |
|
0 |
0 |
0 |
|
r112 |
Estimated payables |
100 700 000 |
51 105 000 |
72 119 000 |
224 195 000 |
|
r113 |
Other payables |
463 000 |
478 000 |
744 000 |
959 000 |
|
r114 |
Bank loans and
financial accommodations |
0 |
0 |
0 |
0 |
|
r115 |
Long-term bank loans |
0 |
0 |
0 |
0 |
|
r116 |
Short-term bank loans |
0 |
0 |
0 |
0 |
|
r117 |
Short-term accommodations |
0 |
0 |
0 |
0 |
|
r118 |
Accruals |
20 335 000 |
27 409 000 |
23 552 000 |
43 767 000 |
|
r119 |
Accrued expenses |
18 165 000 |
27 402 000 |
23 542 000 |
43 767 000 |
|
r120 |
Deferred revenues |
2 170 000 |
7 000 |
10 000 |
0 |
|
|
profit/loss
account |
31.12.2008 (CZK) |
31.12.2009 (CZK) |
31.12.2010 (CZK) |
31.12.2011 (CZK) |
|
|
a1 |
Turnover |
4 814 049 000 |
5 412 044 000 |
6 750 870 000 |
8 673 486 000 |
|
|
a2 |
Revenues from sold goods |
383 685 000 |
713 932 000 |
1 247 440 000 |
876 039 000 |
|
|
a3 |
Expenses on sold goods |
320 294 000 |
495 561 000 |
1 233 425 000 |
744 691 000 |
|
|
a4 |
Sale margin |
63 391 000 |
218 371 000 |
14 015 000 |
131 348 000 |
|
|
a5 |
Production |
4 661 725 000 |
4 757 439 000 |
5 737 285 000 |
7 964 883 000 |
|
|
a6 |
Revenues from own products and services |
4 430 364 000 |
4 698 112 000 |
5 503 430 000 |
7 797 447 000 |
|
|
a7 |
Change in inventory of own products |
224 733 000 |
45 352 000 |
224 596 000 |
165 518 000 |
|
|
a8 |
Capitalization |
6 628 000 |
13 975 000 |
9 259 000 |
1 918 000 |
|
|
a9 |
Production
consumption |
3 005 567 000 |
2 922 417 000 |
3 734 831 000 |
4 694 993 000 |
|
|
a10 |
Consumption of material and energy |
1 815 390 000 |
1 635 190 000 |
2 333 333 000 |
3 688 765 000 |
|
|
a11 |
Services |
1 190 177 000 |
1 287 227 000 |
1 401 498 000 |
1 006 228 000 |
|
|
a12 |
Added value |
1 719 549 000 |
2 053 393 000 |
2 016 469 000 |
3 401 238 000 |
|
|
a13 |
Personnel
expenses |
496 661 000 |
523 555 000 |
652 443 000 |
750 187 000 |
|
|
a14 |
Wages and salaries |
365 960 000 |
389 935 000 |
479 326 000 |
542 587 000 |
|
|
a15 |
Renumeration of board members |
|
0 |
0 |
0 |
|
|
a16 |
Social security expenses and health
insurance |
112 465 000 |
115 958 000 |
151 217 000 |
180 771 000 |
|
|
a17 |
Other social expenses |
18 236 000 |
17 662 000 |
21 900 000 |
26 829 000 |
|
|
a18 |
Taxes and fees |
1 610 000 |
984 000 |
2 418 000 |
1 499 000 |
|
|
a19 |
Depreciations of intangible and tangible
assets |
205 435 000 |
207 693 000 |
279 737 000 |
187 622 000 |
|
|
a20 |
Revenues from disposals
of fixed assets and materials |
19 643 000 |
29 682 000 |
111 957 000 |
45 367 000 |
|
|
a21 |
Revenues from disposals of fixed assets |
782 000 |
1 132 000 |
69 656 000 |
2 406 000 |
|
|
a22 |
Revenues from disposals of materials |
18 861 000 |
28 550 000 |
42 301 000 |
42 961 000 |
|
|
a23 |
Net book value
of disposed fixed assets and materials |
4 592 000 |
27 810 000 |
103 207 000 |
39 285 000 |
|
|
a24 |
Net book value of sold fixed assets |
1 781 000 |
852 000 |
68 275 000 |
95 000 |
|
|
a25 |
Net book value of sold material |
2 811 000 |
26 958 000 |
34 932 000 |
39 190 000 |
|
|
a26 |
Change in operating reserves and
adjustments and complex deferred costs ( + / - ) |
-78 171 000 |
54 873 000 |
-161 757 000 |
56 862 000 |
|
|
a27 |
Other operating revenues |
101 109 000 |
1 289 000 |
15 934 000 |
15 239 000 |
|
|
a28 |
Other operating expenses |
138 576 000 |
68 782 000 |
68 925 000 |
66 728 000 |
|
|
a29 |
Transfer of operating revenues |
|
0 |
0 |
0 |
|
|
a30 |
Transfer of operating expenses |
|
0 |
0 |
0 |
|
|
a31 |
Operating profit
/ loss |
1 071 598 000 |
1 200 667 000 |
1 199 387 000 |
2 359 661 000 |
|
|
a32 |
Revenues from sales of securities and
ownership interests |
|
0 |
281 809 000 |
0 |
|
|
a33 |
Sold securities and ownership interests |
|
0 |
202 000 |
0 |
|
|
a34 |
Revenues from
long-term financial assets |
|
0 |
0 |
0 |
|
|
a35 |
Revenues from shares in controlled and
managed organizations and in accounting units with substantial influence |
|
0 |
0 |
0 |
|
|
a36 |
Revenues from others securities and
ownership interests |
|
0 |
0 |
0 |
|
|
a37 |
Revenues from other long-term financial
assets |
|
0 |
0 |
0 |
|
|
a38 |
Revenues from short-term financial assets |
|
0 |
0 |
0 |
|
|
a39 |
Expenses associated with financial assets |
|
0 |
0 |
0 |
|
|
a40 |
Revenues from revaluation of securities
and derivatives |
|
0 |
0 |
0 |
|
|
a41 |
Cost of revaluation of securities and
derivatives |
|
0 |
0 |
0 |
|
|
a42 |
Change in financial reserves and
adjustments ( + / - ) |
|
0 |
0 |
0 |
|
|
a43 |
Interest revenues |
83 013 000 |
34 612 000 |
27 890 000 |
30 275 000 |
|
|
a44 |
Interest expenses |
|
0 |
0 |
0 |
|
|
a45 |
Other financial revenues |
469 889 000 |
341 145 000 |
255 411 000 |
257 479 000 |
|
|
a46 |
Other financial expenses |
384 234 000 |
511 546 000 |
236 466 000 |
0 |
|
|
a47 |
Transfer of financial revenues |
|
0 |
0 |
0 |
|
|
a48 |
Transfer of financial expenses |
|
0 |
0 |
0 |
|
|
a49 |
Profit / loss from
financial operations ( transactions ) |
168 668 000 |
-135 789 000 |
328 442 000 |
287 754 000 |
|
|
a50 |
Income tax on
ordinary income |
186 879 000 |
216 723 000 |
244 542 000 |
104 789 000 |
|
|
a51 |
Due tax |
234 374 000 |
220 629 000 |
197 424 000 |
209 543 000 |
|
|
a52 |
Tax deferred |
-47 495 000 |
-3 906 000 |
47 118 000 |
-104 754 000 |
|
|
a53 |
Operating profit
/ loss ordinary activity |
1 053 387 000 |
848 155 000 |
1 283 287 000 |
2 542 626 000 |
|
|
a54 |
Extraordinary revenues |
|
0 |
0 |
0 |
|
|
a55 |
Extraordinary expenses |
|
0 |
0 |
0 |
|
|
a56 |
Income tax on
extraordinary income |
|
0 |
0 |
0 |
|
|
a57 |
Due tax |
|
0 |
0 |
0 |
|
|
a58 |
Tax deferred |
|
0 |
0 |
0 |
|
|
a59 |
Operating profit
/ loss extraordinary activity |
|
0 |
0 |
0 |
|
|
a60 |
Transfer profit ( loss ) to partners (+/-) |
|
0 |
0 |
0 |
|
|
a61 |
Profit / loss of
current accounting period (+/-) |
1 053 387 000 |
848 155 000 |
1 283 287 000 |
2 542 626 000 |
|
|
a62 |
Profit / loss
before tax (+/-) |
1 240 266 000 |
1 064 878 000 |
1 527 829 000 |
2 647 415 000 |
|
|
|
Operating cash
flow |
950 781 000 |
537 473 000 |
|
|
|
|
|
Investment cash
flow |
-182 578 000 |
-1 763 838 000 |
|
|
|
|
|
Financial cash
flow |
0 |
|
|
|
|
|
|
Receivables
after due date total |
373 333 000 |
614 923 000 |
284 733 000 |
589 023 000 |
|
|
|
Liabilities
after due date total |
52 437 000 |
277 711 000 |
379 238 000 |
216 275 000 |
|
|
Balance indices |
|
31.12.2008 |
31.12.2009 |
31.12.2010 |
31.12.2011 |
|
|
Return on total assets ROA (in %) |
a62/r1 * 100 |
14,43 |
11,36 |
13,54 |
19,45 |
|
|
Return on equity ROE (in %) |
a62/r68 * 100 |
17,03 |
13,09 |
16,23 |
22,14 |
|
|
Return on sales ROS (in %) |
a62/a1 * 100 |
25,76 |
19,68 |
22,63 |
30,52 |
|
|
Turnover of receivables (in days) |
r49/a1 * 365 |
150,01 |
134,87 |
141,52 |
127,28 |
|
|
Turnover of liabilities (in days) |
r103/a1 * 365 |
61,73 |
51,68 |
76,21 |
41,45 |
|
|
Turnover of inventories (days) |
r32/a1 * 365 |
145,24 |
143,31 |
133,76 |
109,31 |
|
|
Net working capital (in ths. CZK) |
r31 - r102 - r116 - r117 |
5 604 339,00 |
5 338 275,00 |
6 004 974,00 |
8 002 507,00 |
|
|
Ratio of accounts payable to accounts
receivable (in %) |
(r39+r48) / (r91+r102) * 100 |
320,17 |
417,11 |
320,53 |
518,00 |
|
|
Ratio of profit/loss to tangible assets
(in%) |
r3 / a1 * 100 |
39,36 |
55,81 |
52,77 |
48,12 |
|
|
Current ratio |
r31 / (r102+r116+r117) |
6,64 |
6,79 |
4,88 |
7,32 |
|
|
Quick ratio |
(r58+r48) / (r102+r116+r117) |
4,18 |
3,15 |
1,85 |
3,98 |
|
|
Cash ratio |
r58 / (r102+r116+r117) |
1,51 |
0,32 |
0,01 |
0,09 |
|
|
Debt ratio I (in %) |
(1-r68/r67) * 100 |
15,27 |
13,27 |
16,58 |
12,14 |
|
|
Debt ratio II (in %) |
r85/r67 * 100 |
15,04 |
12,98 |
16,37 |
11,82 |
|
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.55.72 |
|
UK Pound |
1 |
Rs.87.95 |
|
Euro |
1 |
Rs.69.66 |
INFORMATION DETAILS
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.